Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus H1N1 vaccine - CPL Biologicals

Drug Profile

Influenza A virus H1N1 vaccine - CPL Biologicals

Alternative Names: CadiFlu; H1N1 influenza VLP vaccine - Novavax; H1N1 virus-like particle pandemic influenza vaccine - Novavax; Monovalent influenza A (H1N1 2009) virus like particle (VLP) vaccine - CPL Biologicals; Swine flu vaccine - Novavax; Unadjuvanted 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine - Novavax

Latest Information Update: 23 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novavax
  • Developer CPL Biologicals; Novavax
  • Class Influenza A virus H1N1 vaccines; Influenza virus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 31 Dec 2012 CPL Biologicals initiates a phase I trial of its Influenza-A virus H1N1 subtype vaccine in India
  • 04 Aug 2011 Final immunogenicity data from a phase II trial in Influenza-A virus H1N1 subtype (Prevention) released by Novavax
  • 01 Mar 2011 Novavax receives a contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of Influenza virus-like particle vaccines in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top